alexa Jagat R Kanwar | Deakin University
ISSN: 2155-9600

Journal of Nutrition & Food Sciences
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Jagat R Kanwar

Jagat R Kanwar Jagat R Kanwar
Nanomedicine-Laboratory of Immunology and Molecular Biomedical Research
School of Medicine (SoM), Faculty of Health
Deakin University

Professor Jagat R Kanwar is the Head and team leader of Nanomedicine-Laboratory of Immunology and Molecular Biomedical Research (NLIMBR), School of Medicine, Faculty of Health, Deakin University, Australia. Professor Kanwar has an international reputation and expertise in investigating fundamental and applied molecular signalling aspects of pathogenesis of cancer, chronic inflammation and neurodegenerative diseases, thereby, leading to the development of treatment strategies from bench to bedside. He has more than 150 research publications in high impact factor and peer reviewed international journals, 27 book chapters and 3 edited books. Prof Kanwar’s research has generated several patents/PCTs with more than five licensed patents for commercialization to BioPharma industry. His group is currently working on drug discovery and nanomedicine for oral and systemic drug delivery of a range of natural bioactive and biomacromolecules (proteins/peptides, siRNAs and aptamers) for targeting survivin, HIF-1α and other apoptotic and inflammatory cell signalling molecules in cancer, chronic inflammation and neurodegenerative disorders. His research combines Immunology with state of the art and cutting edge techniques in Molecular Biology, Biochemistry, Nanobiotechnology and visualization to investigate the pathways in which key molecules are regulated in both normal and disease states. A number of in vitro human cell/tissue based co-culture models for cancers, microbial infections; autoimmune diseases; chronic inflammatory diseases (osteoarthritis, inflammatory bowel disease), gut health, neurodegeneration and immunomodulation have been developed by his group. Kanwar’s main research objective is to understand and target the mechanisms involved at the molecular and sub cellular level which gives us an edge over the prevalent targeting techniques. He carries out both academic and commercial research projects and develops new approaches for the diagnosis, treatment, and nanomedicine based new generation delivery systems. His recent research focus on locked nucleic acid (LNA) LNA-modified aptamers conjugated "double targeted nano-bullet nanocapsules" with natural anti-tumour proteins which specifically target cancer cells.

Research Interest

Our nanomedicine laboratory of immunology and molecular biomedical research (NLIMBR) is discovering the novel and safe targeted nanomedicine based nano-nutraceuticals for cancers, autoimmune disorders and inflammatory diseases. We also vested the molecular diagnosis including role of a non-invasive exosomes in blood, inflammatory sites and cancer tissues. Our research focused on cancer and inflammatory autoimmune diseases aims to investigate the underlying mechanisms involved in apoptosis, autophagy and inflammation by targeting the production of cytokines, chemokines, oxygen radicals and matrix metalloproteinase. Our research also aims to investigate the nanotherapeutics encapsulating peptides, LNA modified aptamers/miRNAs/siRNA in vivo models. We have made significant progress in field of ocular drug delivery and microfluidic and Lab-on-a-Chip devices techniques for cancer cells as well as stem cell capture, disease specific biomarkers and exosomes.


Curcumin Regulates Colon Cancer by Inhibiting P-Glycoprotein in In-situ Cancerous Colon Perfusion Rat Model
Prasad Neerati, Yakkanti A. Sudhakar and Jagat R Kanwar
Research Article: J Cancer Sci Ther/Vol.5.9 313-319(2013)
DOI: 10.4172/1948-5956.1000221
Survivin in Cancer: A Spider in the Web
Sishir K Kamalapuram, Rupinder K Kanwar and Jagat R Kanwar
Editorial: J Nanomed Nanotechnol 2012, 3:e118
DOI: 10.4172/2157-7439.1000e118
Multifunctional Nanotherapeutics: “The Engines of Healing”
Jagat R Kanwar
Editorial: J Cancer Sci Ther/Vol.4.12 xxiii-xxiv (2012)
DOI: 10.4172/1948-5956.1000e115
Multifunctional Nanotheranostics: Do We Really Need Them?
Jagat R Kanwar
Editorial: J Cancer Sci Ther/Vol.4.11 xxii-xxii (2012)
DOI: 10.4172/1948-5956.1000e114
Natural Therapeutics Targeting Survivin
Jagat R Kanwar, Rasika M Samarasingie and Rupinder K Kanwar
Editorial: Biochem Anal Biochem 2012, 1: e121
DOI: 10.4172/2161-1009.1000e121
Influence of Curcumin on Pioglitazone Metabolism and Pk/Pd: Diabetes Mellitus
Prasad Neerati, Ravi Karan M and Jagat R Kanwar
Research Article: J Diabetes Metab 2012, S6-003
DOI: 10.4172/2155-6156.S6-003
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version